Lv31
360 积分 2026-03-13 加入
RCLARITY : A Prospective Phase II Study of Rituximab Combined With Lenalidomide and Chidamide ( RLC ) for the Treatment of Relapsed/Refractory Angioimmunoblastic T‐Cell Lymphoma
1个月前
已完结
SOHO State of the Art Updates and Next Questions: How Should We Risk Stratify and Tailor Therapy for Patients With High Tumor Burden Follicular Lymphoma? A Systematic Review
2个月前
已关闭
The treatment of marginal zone lymphoma
2个月前
已完结
MCL-528 Real-World (RW) Comparative Effectiveness of Covalent Bruton Tyrosine Kinase Inhibitors (cBTKis) Among Patients With Relapsed/Refractory Mantle Cell Lymphoma (R/R MCL)
2个月前
已关闭
Zanubrutinib plus Ixazomib and Dexamethasone in Newly Diagnosed Symptomatic Waldenström Macroglobulinemia: A Phase II Study
2个月前
已完结
Zanubrutinib, lenalidomide, rituximab, temozolomide ± methotrexate as first‐line treatment for primary central nervous system lymphoma: A prospective, open‐label, multicentre clinical trial
3个月前
已完结
Zanubrutinib versus ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia and small lymphocytic lymphoma: health-related quality of life in a subgroup of Chinese patients in the ALPINE trial
3个月前
已关闭
Prognostic significance of clinical risk models and genomic alterations in Waldenström macroglobulinemia before or after the BTK inhibitor era
3个月前
已完结
A real-world multicenter study of first-line zanubrutinib-based therapy for diffuse large B-cell lymphoma
3个月前
已完结
SOHO State of the Art Updates and Next Questions | Management of Primary Central Nervous System Lymphoma
3个月前
已关闭
皖公网安备34019202002308
